VEGF-C: Lymphangiogenesis, VEGFR-3 Signaling, and Anti-Lymphangiogenic Research Tools

# VEGF-C: Lymphangiogenesis, VEGFR-3 Signaling, and Anti-Lymphangiogenic Research Tools

Category: Peptide Guides | Read Time: 13 min | Tags: VEGF-C, VEGFR-3, lymphangiogenesis, lymphatic endothelium, tumor metastasis, neuropilin-2, CCBE1, anti-lymphangiogenic

---

For Research Use Only. Not for human or animal therapeutic use.

---

Introduction

Vascular endothelial growth factor C (VEGF-C) is the founding ligand of the lymphangiogenic arm of the VEGF family — a group of five structurally related glycoproteins (VEGF-A, -B, -C, -D, and PlGF) that collectively govern vascular and lymphatic development. While VEGF-A dominates blood vessel biology through VEGFR-2, VEGF-C exerts its principal effects on lymphatic endothelial cells (LECs) via VEGFR-3 (Flt4), driving lymphatic vessel sprouting, migration, proliferation, and survival. Its discovery by Joukov et al. in 1996 resolved a decades-old puzzle: how does the lymphatic system, which shares no angiogenic growth factor with blood vessels, expand and regenerate? The answer was a dedicated receptor tyrosine kinase (VEGFR-3) and a dedicated ligand (VEGF-C/D) whose expression and processing are tightly regulated to prevent lymphatic overgrowth.

This mechanistic review covers VEGF-C gene structure and propeptide processing, VEGFR-3 signal transduction, the role of co-receptors (neuropilin-2, CCBE1, LYVE-1), physiological lymphangiogenesis, pathological contributions to tumor metastasis and lymphedema, and the research tools available to manipulate the VEGF-C/VEGFR-3 axis experimentally.

---

Gene Organization and Propeptide Processing

The human VEGFC gene maps to chromosome 4q34.3 and encodes a 419-amino-acid prepropeptide. Unlike VEGF-A, which is predominantly regulated at the transcriptional and mRNA stability level, VEGF-C bioactivity is controlled post-translationally through a stepwise proteolytic maturation cascade.

Propeptide Architecture

The full-length VEGF-C precursor consists of:

• •N-terminal signal peptide (residues 1–22): directs secretion
• •N-terminal propeptide (NPDP): 103 residues preceding the VEGF homology domain (VHD)
• •VEGF homology domain (VHD): the core receptor-binding module, residues 104–215, shared with all VEGF family members in secondary structure
• •C-terminal cysteine-rich (CTCK) domain: unique to VEGF-C and VEGF-D, contains a "silk-homology domain" with multiple disulfide bonds that retains the propeptide in an intramolecular association

Proteolytic Activation Steps

Step 1 — Furin/PC5 cleavage: The CTCK domain is cleaved intracellularly (by proprotein convertases furin and PC5) at the sequence HSIIR↓, releasing the C-terminal propeptide. The resulting intermediate retains the N-terminal propeptide and exhibits low VEGFR-3 affinity and essentially no VEGFR-2 affinity.

Step 2 — ADAMTS3/Collagen- and calcium-binding EGF domain-containing protein 1 (CCBE1) cleavage: The co-factor CCBE1 presents the N-terminal propeptide to ADAMTS3 for cleavage at Ala103↓Asn104, releasing the N-propeptide and generating "mature VEGF-C" (the VHD alone, ~21 kDa non-reduced). Mature VEGF-C binds VEGFR-3 with ~700-fold higher affinity than the partially processed form and, uniquely, acquires the ability to bind VEGFR-2 (Kd ~200 nM), conferring weak angiogenic activity (Joukov et al., EMBO J, 1997; Jeltsch et al., J Exp Med, 2014).

CCBE1 as a morphogen co-regulator: CCBE1 is expressed by sub-populations of mesenchymal cells adjacent to developing lymphatics. CCBE1 loss-of-function mutations cause Hennekam syndrome (lymphedema, lymphangiectasia, intellectual disability) — a human genetic proof-of-concept that the ADAMTS3/CCBE1 processing step is non-redundant in vivo (Alders et al., Nat Genet, 2009). This makes CCBE1 a critical spatial regulator: VEGF-C processing occurs only where CCBE1-expressing mesenchyme is present, restricting lymphangiogenic competence to specific tissue zones.

---

VEGFR-3 (Flt4): Structure and Signal Transduction

VEGFR-3 is a class III receptor tyrosine kinase with seven immunoglobulin-like (Ig-like) extracellular domains (ECDs), a single transmembrane helix, and a split kinase domain separated by a 70-residue kinase insert. It is expressed almost exclusively on LECs in adult tissues, although fetal blood endothelium also expresses VEGFR-3 transiently (Kaipainen et al., PNAS, 1995).

Ligand Binding and Receptor Dimerization

VEGF-C binds VEGFR-3 through Ig-like domains 1 and 2 of the receptor ECD, analogous to VEGF-A binding to VEGFR-2 Ig domains 2 and 3. VEGF-C forms non-covalent homodimers (like all VEGF family members) that engage two VEGFR-3 ectodomains simultaneously, inducing receptor dimerization and trans-autophosphorylation. Key phosphorylation sites in the VEGFR-3 cytoplasmic domain:

• •Tyr1230/Tyr1231 (activation loop): primary kinase-activating phosphorylation sites; equivalent to VEGFR-2 Tyr1054/Tyr1059
• •Tyr1337: recruits Grb2 → Sos → Ras → ERK1/2 proliferative cascade
• •Tyr1363: docking site for Shc and CrkII; links to PI3K/Akt and Rac1 for migration
• •Tyr833: recruits p85 subunit of PI3K directly

PI3K/Akt/mTOR: The Survival and Growth Axis

PI3K activation by VEGFR-3 generates PIP3, which recruits and activates PDK1 → Akt. Key Akt substrates in LECs:

• •FOXO1/FOXO3a phosphorylation (nuclear exclusion) → suppresses pro-apoptotic BIM, PUMA; promotes LEC survival
• •mTORC1 activation (via TSC2 phosphorylation) → S6K1 and 4E-BP1 phosphorylation → enhanced ribosome biogenesis and cap-dependent translation; drives LEC proliferation
• •eNOS Ser1177 phosphorylation → lymphatic NO production → vessel dilation and permeability regulation

ERK1/2: The Sprouting and Migration Axis

Grb2/Sos → Ras → RAF → MEK → ERK1/2 drives:

• •Cyclin D1 upregulation → G1/S transition
• •ETS transcription factor phosphorylation (ETS-1, ETS-2) → upregulation of VEGFR-3 itself (positive feedback), PROX1, and LYVE-1 in LECs
• •MMP-1, MMP-9 induction → ECM remodeling for lymphatic sprouting

VEGFR-3/VEGFR-2 Heterodimerization

At high VEGF-C concentrations (mature form), VEGFR-3 can heterodimerize with VEGFR-2 on LECs (which co-express VEGFR-2 at lower levels than blood endothelium). VEGFR-3/VEGFR-2 heterodimers generate a distinct phosphorylation signature and drive more potent PI3K/Akt signaling than VEGFR-3 homodimers — a mechanism that may amplify lymphangiogenic responses at high ligand concentrations or at VEGF-A/VEGF-C co-expression sites (Dixelius et al., Mol Cell Biol, 2003).

---

Co-Receptors: Neuropilin-2 and LYVE-1

Neuropilin-2 (NRP2)

NRP2 is a single-pass transmembrane co-receptor expressed on lymphatic endothelium and tumor-associated lymphatics. It binds the C-terminal heparin-binding domain of VEGF-C and -D (distinct from VEGFR-3 binding sites), forming a tripartite complex that enhances VEGFR-3 dimerization efficiency and downstream PI3K/Akt signaling amplitude. NRP2 does not have intrinsic kinase activity.

NRP2 knockout mice show severely hypoplastic lymphatic networks with reduced branching and impaired lymphatic valve formation (Yuan et al., Development, 2002), confirming NRP2 is a genuine signaling co-receptor rather than a passive decoy. In tumor biology, NRP2 overexpression on tumor-associated lymphatics correlates with increased metastatic burden in multiple cohorts, and anti-NRP2 antibodies reduce VEGF-C-driven lymphangiogenesis in xenograft models.

LYVE-1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1)

LYVE-1 is a hyaluronan (HA) receptor expressed almost exclusively on LECs and liver sinusoidal endothelium. It binds the HA coat on circulating leukocytes and tumor cells, facilitating their docking to lymphatic vessels. While not a direct VEGF-C signaling receptor, LYVE-1 marks lymphatic identity and is widely used as an LEC marker in histology (along with PROX1, podoplanin/D2-40, and VEGFR-3).

---

Physiological Lymphangiogenesis: Embryonic and Adult

Embryonic Lymphatic Development

Lymphatic vessels arise from a subpopulation of PROX1+ venous endothelial cells in the cardinal vein (CV) at E9.5–10.5 in mice. These lymphatic endothelial progenitors (LEPs) bud from the CV and migrate laterally to form the primary lymph sac. VEGF-C/VEGFR-3 signaling is required for: (1) induction of PROX1 expression in CV endothelium, (2) budding from the CV, and (3) subsequent lymphatic network expansion.

Vegfc and Vegfr3 homozygous null mice die at E15.5–17.5 with severe fluid accumulation and failure to develop functional lymphatics — among the most penetrant vascular phenotypes in the mouse genome. Heterozygous Vegfc+/- mice survive but develop lymphedema with incomplete penetrance, modeling human Milroy disease-like phenotypes (Karkkainen et al., Nat Genet, 2001).

Adult Lymphangiogenesis

In adult tissue, lymphangiogenesis occurs in:

• •Wound healing: VEGF-C from macrophages and keratinocytes drives lymphatic regeneration following injury; impaired lymphangiogenesis in wounds leads to chronic edema.
• •Inflammation: VEGF-C produced by inflammatory macrophages, mast cells, and DCs expands lymphatic networks in chronically inflamed tissues (e.g., RA synovium, IBD mucosa), facilitating immune cell trafficking and antigen clearance to lymph nodes.
• •Pregnancy: Uterine decidua undergoes VEGF-C-driven lymphangiogenesis to manage interstitial fluid and immunological tolerance.
• •Exercise adaptation: Diaphragm and skeletal muscle undergo modest VEGF-C-driven lymphatic expansion in response to sustained aerobic exercise.

---

VEGF-C in Tumor Biology: Lymphatic Metastasis

The connection between VEGF-C and tumor lymphatic metastasis was established by Skobe et al. and Stacker et al. (Nat Med, 2001) who showed that VEGF-C overexpression in breast cancer and melanoma cell lines dramatically increased intratumoral and peritumoral lymphangiogenesis and regional lymph node metastasis, while anti-VEGFR-3 blocking antibodies attenuated these effects.

Mechanisms of Tumor-Driven Lymphangiogenesis

VEGF-C sources in the TME:

• •Primary tumor cells (autocrine/paracrine): many carcinomas upregulate VEGF-C expression downstream of oncogenic RAS/MAPK, HIF-1α (hypoxia), and NF-κB
• •Tumor-associated macrophages (TAMs): M2-polarized TAMs are major VEGF-C producers in the TME; macrophage VEGF-C correlates with lymphatic vessel density and poor prognosis in gastric, breast, and colorectal cancers
• •Cancer-associated fibroblasts (CAFs): stromal fibroblasts co-produce VEGF-C and VEGF-D under TGF-β stimulation
• •Mast cells: degranulating mast cells release preformed VEGF-C from granules, providing rapid bolus delivery

Peritumoral vs. intratumoral lymphatics:

Tumor-associated lymphatics are predominantly located at the tumor-stroma interface (peritumoral). Intratumoral lymphatics, while often collapsed under tumor pressure, may still function as metastatic conduits when interconnected with functional peritumoral networks. Peritumoral lymphatic vessel density (LVD), scored by LYVE-1 or D2-40 IHC, is a validated prognostic biomarker in breast, gastric, and head-and-neck cancers.

Lymph Node Pre-Metastatic Niche

VEGF-C secreted by primary tumors reaches sentinel lymph nodes (SLNs) via lymphatic drainage before tumor cells arrive, inducing LN lymphangiogenesis (LN sinus expansion, high endothelial venule remodeling) that creates a permissive pre-metastatic niche. VEGF-C-driven LN lymphangiogenesis enhances the homing efficiency of subsequently arriving tumor cells, explaining why patients with VEGF-C-high primaries show earlier and more efficient LN colonization (Hirakawa et al., J Exp Med, 2005).

VEGF-C-Independent Lymphangiogenic Loops

Not all tumor lymphangiogenesis is VEGF-C-driven. Emerging mechanisms include:

• •Angiopoietin-2 (Ang-2)/Tie-2: promotes lymphatic permeability and remodeling
• •HGF/Met: activates LEC migration independently of VEGFR-3
• •PDGF-BB: via PDGFR-β on LEC pericytes, stabilizes lymphatics under high VEGF-C
• •Lysophosphatidic acid (LPA)/LPA receptors: promotes LEC migration and tube formation; relevant in ovarian cancer

---

Lymphedema: Loss-of-Function Phenotypes

Primary lymphedema arises from genetic defects in lymphatic development genes, with VEGF-C/VEGFR-3 pathway mutations accounting for ~30% of familial cases:

Secondary lymphedema (most commonly following cancer surgery/radiation that ablates lymph nodes and lymphatics) involves VEGF-C depletion in the affected tissue segment. VEGF-C gene therapy (AAV-VEGF-C) and VEGF-C protein delivery are in early-stage investigation as tools for lymphatic regeneration in secondary lymphedema models.

---

Research Tools for VEGF-C/VEGFR-3 Axis Manipulation

Recombinant VEGF-C Protein

Commercial recombinant VEGF-C (e.g., R&D Systems #752-VC) is typically expressed as the mature VHD form in HEK293 or CHO cells, bypassing the need for CCBE1/ADAMTS3 processing. Key specifications:

• •Molecular weight: ~21 kDa (reducing), ~42 kDa (non-reducing, disulfide-linked homodimer)
• •EC50 for VEGFR-3 phosphorylation: 1–10 ng/mL in HDLECs (Human Dermal Lymphatic Endothelial Cells)
• •Storage: reconstitute in PBS + 0.1% BSA at 100 µg/mL; aliquot; store at −80°C
• •Avoid carrier-free formulations for low-concentration assays (<10 ng/mL) due to adsorption losses

VEGF-C Mutants as Research Tools

VEGF-C C156S (VEGF-C156S): A single point mutation (Cys156Ser) in the VHD that abolishes VEGFR-2 binding while preserving high-affinity VEGFR-3 binding. VEGF-C156S is the standard tool for VEGFR-3-selective lymphangiogenic stimulation, separating lymphangiogenic (VEGFR-3) from angiogenic (VEGFR-2) outcomes (Joukov et al., J Biol Chem, 1998). Working concentration: 100–500 ng/mL for robust lymphangiogenic response.

VEGF-C DIIΔ (truncated): Deletion of Ig-like domain III of VEGFR-3 binding site; used to study NRP2-independent VEGFR-3 signaling.

VEGFR-3 Blocking Antibodies

• •hF4-3C5 (mF4-31C1): Rat anti-mouse VEGFR-3 blocking monoclonal (ImClone/BioLegend); recognizes the VEGF-C binding domain of mouse VEGFR-3; used extensively in in vivo xenograft lymphangiogenesis studies at 25–50 mg/kg i.p. in mice. Does not cross-react with human VEGFR-3.
• •IMC-3C5 (ramucirumab precursor lineage): Human anti-VEGFR-3 antibody; blocks VEGF-C binding; used in xenograft models with human tumor cells. Blocks both VEGF-C and VEGF-D binding.
• •Anti-human VEGFR-3 (clone 9D9, Abcam/Cell Signaling): For IHC/flow cytometry; not a blocking antibody; detects VEGFR-3 extracellular domain on LECs.

Small-Molecule VEGFR Inhibitors

Multiple multi-target VEGFR kinase inhibitors cover VEGFR-3:

• •Axitinib (AG-013736): IC50 VEGFR-3 ~1 nM, VEGFR-2 ~0.2 nM, VEGFR-1 ~0.1 nM; highly potent pan-VEGFR inhibitor used to eliminate all VEGFR signaling in LEC experiments; 10–100 nM in cell-based assays.
• •Pazopanib: IC50 VEGFR-3 ~47 nM; less potent on VEGFR-3 than axitinib; also inhibits PDGFR and Kit.
• •Sorafenib: IC50 VEGFR-3 ~20 nM; additionally inhibits RAF1, B-RAF; confounds ERK pathway interpretations in VEGFR-3 studies — use axitinib instead when ERK specificity is needed.
• •SAR131675: Selective VEGFR-3 inhibitor (IC50 ~23 nM VEGFR-3, >100× selectivity over VEGFR-1/2); the best-characterized VEGFR-3-selective tool compound for separating VEGFR-3 from VEGFR-2 signaling in dual-receptor contexts. Use at 100 nM–1 µM in cellular assays.

Anti-VEGF-C Antibodies (Neutralizing)

• •R&D Systems MAB752: Mouse anti-human VEGF-C neutralizing antibody; neutralization dose ~1 µg/mL vs. 50 ng/mL VEGF-C. Used in conditioned medium neutralization experiments.
• •Clone VG76e (Abcam): Widely used for VEGF-C detection by ELISA and IHC; not a functional blocking antibody.

VEGF-D: The Paralog

VEGF-D undergoes identical CCBE1/ADAMTS3 maturation as VEGF-C and binds VEGFR-3 with similar affinity. VEGF-D additionally binds VEGFR-2 (mature form) and is the only VEGF family member with demonstrated pre-formed peptide localization in mast cell granules. In lymphangiogenesis research, VEGF-C and VEGF-D are often studied in parallel with selective neutralization to distinguish their relative contributions.

---

Experimental Protocols

Protocol 1: HDLEC Tube Formation (Matrigel)

1. Coat 96-well plates with growth factor-reduced Matrigel (Corning 354230), 50 µL/well; polymerize 30 min at 37°C.

2. Seed 2 × 10⁴ HDLECs (PromoCell or Lonza) per well in EBM-2 + 0.5% FBS (starvation conditions).

3. Add VEGF-C (50–200 ng/mL) or VEGF-C156S (100–500 ng/mL) ± SAR131675 (1 µM) or axitinib (100 nM).

4. Image at 4h and 8h; quantify tube length, branch points, and nodes using ImageJ Angiogenesis Analyzer plugin.

5. Controls: basal (no growth factor), VEGF-A (50 ng/mL, blood endothelial positive control), VEGF-C + anti-VEGFR-3 (10 µg/mL; specificity control).

Protocol 2: VEGFR-3 Phosphorylation by Western Blot

1. Starve HDLECs (EBM-2, 0.1% BSA, no growth factors) for 4h at 37°C.

2. Pre-treat ± SAR131675 (100 nM–1 µM) for 30 min; then stimulate with VEGF-C156S (100 ng/mL) for 10 min at 37°C.

3. Lyse in RIPA + phosphatase inhibitors (Na₃VO₄ 1 mM, NaF 10 mM) + protease inhibitors.

4. Immunoprecipitate VEGFR-3 with anti-VEGFR-3 (clone 9D9, 2 µg per 500 µg protein) + Protein A/G beads.

5. Blot with anti-phosphotyrosine (4G10, Millipore, 1:1000) or anti-pVEGFR-3 Y1230/1231 (Cell Signaling #4473, 1:1000); strip and re-probe total VEGFR-3.

6. Alternatively: sandwich ELISA-based VEGFR-3 phospho assay (PathScan, Cell Signaling) avoids IP requirement.

Protocol 3: LEC Sprouting from Spheroids

1. Mix 2500 HDLECs per 200 µL EBM-2 + 0.25% Methocel in U-bottom 96-well plate; centrifuge 400×g 10 min → hanging drop spheroids form overnight.

2. Harvest spheroids; embed in collagen I gel (2 mg/mL rat tail collagen, pH 7.4, neutralized with NaOH) in 48-well plates.

3. Overlay with EBM-2 ± VEGF-C (50–200 ng/mL) ± SAR131675 (500 nM).

4. Image at 24h; quantify cumulative sprout length and sprout number per spheroid (ImageJ).

5. This assay measures invasion + migration + proliferation collectively, better approximating in vivo lymphangiogenic sprouting than 2D scratch assays.

Protocol 4: VEGF-C ELISA from Conditioned Medium

1. Collect conditioned medium (CM) from tumor cells or stroma (serum-free, 24h), centrifuge 400×g 10 min to remove cell debris.

2. Concentrate if needed: 10 kDa MWCO Amicon Ultra spin column, 10× concentration.

3. Use human VEGF-C ELISA kit (R&D Systems DY752 DuoSet or Abcam ab100534): detection range 31–2000 pg/mL; optimal sample dilution 1:2 to 1:10 for CM from most tumor cell lines.

4. Note: ELISA typically detects both pro-VEGF-C and mature VEGF-C; if isoform distinction is needed, validate with VEGF-C-specific antibodies against pro- vs. mature forms by IP-WB.

Protocol 5: In Vitro Lymphangiogenesis Blockade (Tumor-Stroma Co-culture)

1. Culture tumor cells (VEGF-C-expressing line, e.g., MDA-MB-231 breast or HCT116 colorectal) in upper Transwell insert (0.4 µm pore).

2. HDLECs seeded in lower chamber on fibronectin-coated surface in EBM-2 + 1% FBS.

3. After 48h co-culture, quantify LEC proliferation (EdU incorporation), migration (wound-healing), and VEGFR-3 phosphorylation.

4. Add neutralizing anti-VEGF-C antibody (MAB752, 1 µg/mL) or SAR131675 (500 nM) to verify VEGF-C/VEGFR-3 axis dependency.

5. Multiplex conditioned medium analysis (Luminex) for VEGF-C, VEGF-A, Ang-2 to profile tumor lymphangiogenic secretome.

---

VEGF-C in Immune Function: Beyond Angiogenesis

Lymphatic vessels are not passive drainage conduits — they actively regulate immune surveillance and tolerance:

• •Dendritic cell (DC) trafficking: VEGF-C-driven lymphangiogenesis in inflamed tissue increases DC efferent migration to lymph nodes, amplifying adaptive immune responses. Conversely, tumor-driven lymphangiogenesis may accelerate tumor antigen presentation or alternatively promote tolerance induction depending on the DC subset delivered.
• •Regulatory T cell trafficking: CCL21 produced by LECs (upregulated by VEGF-C/VEGFR-3) recruits CCR7+ Tregs and DCs into lymphatics; VEGF-C-high tumors show elevated intratumoral Treg densities in some contexts.
• •Self-tolerance: The lymph node sinus is a site of peripheral self-tolerance where LEC-expressed VEGFR-3 and antigen-presenting machinery collaborate to delete autoreactive T cells; lymphedema (reduced LEC function) correlates with autoimmune sequelae in some patients.
• •Gut immune surveillance: Lacteal VEGFR-3+ lymphatics in intestinal villi transport dietary lipids and IgA; VEGFR-3 signaling maintains lacteal integrity — Vegfr3 conditional knockout in adult intestinal lymphatics causes fat malabsorption and mucosal immune dysregulation.

---

Transcriptional Regulation of VEGF-C

Hypoxia (HIF-1α)

VEGFC promoter contains functional hypoxia response elements (HREs). Hypoxia-inducible factor 1α (HIF-1α) binds HREs and upregulates VEGF-C transcription — less robustly than VEGF-A (which has ~10 HREs vs. VEGF-C ~2) but physiologically significant in solid tumor hypoxic cores. The combination of VEGF-A (angiogenic) and VEGF-C (lymphangiogenic) upregulation under hypoxia creates a dual pro-vascularization response.

Inflammatory Cytokines (TNF-α, IL-1β)

NF-κB binding sites in the VEGFC promoter mediate upregulation by TNF-α and IL-1β, explaining the lymphangiogenic response in chronically inflamed tissue. COX-2-derived prostaglandins (PGE2) further amplify VEGF-C transcription via EP2/EP4 receptors and cAMP/PKA signaling. These overlapping inflammatory inputs make VEGF-C a node where chronic inflammation and lymphangiogenesis intersect.

Oncogenic Signaling

• •RAS/MAPK: Activating KRAS/NRAS mutations drive VEGF-C upregulation via transcription factors ETS-1 and AP-1
• •ErbB2 (HER2): HER2 overexpression activates VEGF-C via PI3K/Akt/NF-κB and MAPK/ETS-1; one mechanism linking HER2+ breast cancer to elevated LVD and poor prognosis
• •EGFR: Transcriptional VEGF-C upregulation downstream of EGFR/PI3K in squamous cell carcinomas

---

Crosstalk with VEGF-A: Complementary and Antagonistic Interactions

VEGF-A and VEGF-C are co-expressed in most solid tumors and can cooperate or antagonize:

Cooperation: Both ligands converge on VEGFR-2 signaling in dual-receptor-expressing cells (LECs, some tumor endothelium). VEGF-A promotes initial blood vessel formation that brings oxygen and nutrients; VEGF-C expands the lymphatic network that drains fluid and carries away immune cells and tumor-shed antigens.

Antagonism: High-dose VEGF-A can paradoxically inhibit lymphangiogenesis by VEGFR-2-mediated downregulation of PROX1 in LECs, transdifferentiating lymphatic toward blood endothelial identity. This is the mechanistic basis for the "blood lymphatic endothelial plasticity" phenomenon seen in hemangiomas and some VEGF-A-overexpressing tumors where lymphatics lose their identity markers.

VEGF-A/VEGF-C gradient sensing: In development, spatially segregated VEGF-A and VEGF-C gradients help specify blood vs. lymphatic vessel trajectories. Experimental perturbation of this balance (e.g., AAV-VEGF-C delivery in blood-vessel-rich tissue) can redirect blood endothelial progenitors toward lymphatic fate.

---

Key Research Tools Summary

---

Conclusion

VEGF-C occupies a unique position in vascular biology as the master regulator of lymphangiogenesis — a process as essential to tissue homeostasis as angiogenesis, yet far less studied until the past two decades. Its multi-step propeptide processing by CCBE1/ADAMTS3 provides a sophisticated spatial and temporal control mechanism, ensuring that lymphangiogenic competence is restricted to tissue zones where both ligand and processing machinery coincide.

The VEGF-C/VEGFR-3 axis is now established as a driver of tumor lymphatic metastasis across >20 cancer types, with peritumoral lymphatic vessel density as a validated prognostic biomarker. The mechanistic tools available — from the VEGFR-3-selective VEGF-C C156S mutant to the highly selective SAR131675 kinase inhibitor — allow dissection of lymphangiogenic vs. angiogenic outputs with precision not previously possible.

Critical open questions include: How do VEGF-C-driven lymphatics interact with checkpoint immunotherapy responses — do pro-lymphangiogenic strategies enhance or impair anti-tumor immunity? What is the functional significance of the VEGFR-3/VEGFR-2 heterodimer relative to the VEGFR-3 homodimer in LECs? And can VEGF-C delivery strategies be optimized to regenerate functional lymphatics in secondary lymphedema without inadvertently promoting tumor lymphangiogenesis?

---

References

1. Joukov V, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15(2):290–298.

2. Jeltsch M, et al. CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3–mediated vascular endothelial growth factor-C activation. J Exp Med. 2014;211(9):2653–2680.

3. Karkkainen MJ, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2001;25(2):153–159.

4. Skobe M, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7(2):192–198.

5. Stacker SA, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7(2):186–191.

6. Hirakawa S, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005;201(7):1089–1099.

7. Alders M, et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet. 2009;41(12):1272–1274.

8. Yuan L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development. 2002;129(20):4797–4806.

9. Kaipainen A, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. PNAS. 1995;92(8):3566–3570.

10. Dixelius J, et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. Mol Cell Biol. 2003;23(15):5523–5531.

11. Joukov V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. J Biol Chem. 1997;272(52):33013–33020.